Mohammad Jahan Shams

Dr. Mohammad Jahan Shams

Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in Bangabandhu Sheikh Mujib Medical University Journal
Verified
Journal Article
Open access
PDF file
HAHasan Shahrear Ahmed
Hasan Shahrear Ahmed
KMKrisna Rani Majumder
Krisna Rani Majumder
MSMohammad Jahan Shams
Mohammad Jahan Shams
AHAfm Anwar Hossain
Afm Anwar Hossain
MRMizanur Rahman
Mizanur Rahman
Molecular factors play an important role in the management and treatment outcome of breast cancer. Molecular subtyping has been developed depending upon estrogen and progesterone receptors, human epidermal growth factor receptor-2 and ki76 level. This cross-sectional study was done to assess the molecular subtypes of locally advanced breast cancer and its associated risk factors. Total 94 patients with locally advanced breast cancer were included in the study. The mean age was 42.6 years with a standard deviation of 9.56. In total, 91.5 percent of respondents had menarche at or after the age of 12, and 26.6 % had used hormonal contra- ception in the past. Tobacco users and positive family history were found in 21.2% and 5.35% of the cases. Among the patients, 3.4 % of cases had their first childbirth after the age of 30 and 95.5% of patients feed their babies from their both breasts. Among 94 cases 5 did not have any child. Estrogen receptor was found positive in 35% of cases, progesterone receptor-positive patient was 33% and HER-2 was found positive in 39.4% of cases. Ki-67 level was found high in 66% of cases. Among the 94 cases, the Luminal A subtype was found in 18% and the Lumi- nal B subtype was found in 27.7% cases. The human epidermal growth factor receptor-2 subtype was found relatively less frequent than Luminal type B (24.5% vs. 27.7%). Triple-neg- ative breast cancer was most commonly diagnosed among the patients (almost 30%). The increased number of triple-negative variants signifies poor prognostic outcomes. The risk factor of breast cancer did not show any statistical correlation with molecular subtypes. BSMMU J 2021; 14(3): 57-61

31 January 2021 in Bangladesh Medical Journal
Verified
Journal Article
Closed access
PDF file
STSajib Kumar Talukdhar
Sajib Kumar Talukdhar
SASarwar Alam
Sarwar Alam
MBMd Abdul Bari
Md Abdul Bari
SSSadia Sharmin
Sadia Sharmin
MSMohammad Jahan Shams
Mohammad Jahan Shams
ADArnob Barua David
Arnob Barua David
In Bangladesh, the head and neck cancer is one of the most prevalent cancers. The goal of this study was to assess at the clinicopathological characteristics of individuals with head and neck cancer. This descriptive, cross-sectional study was conducted from July to December 2018, 286 patients with head and neck cancer were included at Bangabandhu Sheikh Mujib Medical University (BSMMU), Department of Clinical Oncology. A pre-made questionnaire was used to collect data from patients during face-to-face interviews. The mean age of the patients was 56.27 (±12.23) years. The bulk of the cases (77.6%) were male, and the most of the patients consumed tobacco (86%). The most common histological type among the patients was squamous cell carcinoma (92%). In terms of primary tumor location, the oral cavity (36%) was the most prevalent. Patients were most often found in stages III (32.2%) and IV (34.6%). In conclusion, head and neck cancer occurs mainly in males and tobacco users. Squamous cell carcinoma is the most frequent histological form, with the oral cavity as the main location of tumors. The majority of the patients are in advanced stages. Bangladesh Med J. 2021 January; 50(1) : 23-26

25 February 2025 in Cureus
Verified
Journal Article
Open access
PDF file
SBShourov Biswas
Shourov Biswas
MRMasudur Rahman
Masudur Rahman
SASarwar Alam
Sarwar Alam
MHMostafa S. Haque
Mostafa S. Haque
EFEkram B. Faruq
Ekram B. Faruq
SBSoma Banerjee
Soma Banerjee
Background and aim: Neoadjuvant chemotherapy with doxorubicin (A) and cyclophosphamide (C) followed by taxane (T) (AC followed by T) is one of the standard regimens in locoregionally advanced breast cancer. Paclitaxel, a taxane, can be given either in a three-weekly or a weekly schedule. The aim of this study was to compare the efficacy in terms of the clinical and pathological response of three-weekly paclitaxel with weekly paclitaxel in the treatment of human epidermal growth factor receptor 2 (HER2)-negative, stage III breast cancer. Materials and methods: A quasi-experimental study was conducted from April 2022 to October 2023 in two centers in Dhaka, Bangladesh. Sixty-six patients were enrolled and divided equally into two arms. Arm-A patients received four cycles of AC followed by paclitaxel (175 mg/m2) three-weekly for four cycles. Patients in Arm-B received four cycles of AC followed by paclitaxel (80 mg/m2) weekly for 12 weeks. Patients were evaluated before, during, and after the completion of the chemotherapy to assess clinical outcomes and were assessed for the pathological response after surgical management. Observations and results: Pathological complete response (pCR) was achieved in 15 (25%) patients. Four patients (13.33%) in Arm A and 11 patients (36.66%) in Arm B had pCR. The difference was statistically significant (p 0.037). The p-value was 0.219 for response at the primary site and 0.13 for response in axillary disease. In both arms, patients with triple-negative receptor status had increased pCR (22.22% or two patients out of nine in Arm A, and 85.71% or six patients out of seven in Arm B) in comparison to hormone receptor (estrogen receptor (ER) and/or progesterone receptor (PR)) positive tumors (9.52% or two patients out of 21 in Arm A, and 21.74% or five patients out of 23 in Arm B). However, these differences were not significant. Conclusion: After three-weekly administrations of four cycles of AC, the weekly administration of paclitaxel was found to be more effective in comparison to three-weekly administration of paclitaxel.

11 April 2023 in SAS Journal of Medicine
Verified
Journal Article
Closed access
RJRajani Jha
Rajani Jha
SASarwar Alam
Sarwar Alam
ABA. Bari
A. Bari
KSKhandokar Samsujjaman
Khandokar Samsujjaman
MSMohammad Jahan Shams
Mohammad Jahan Shams
MJMinu Jha
Minu Jha
Background: Gastric carcinoma is one of the commonest cancers in Bangladesh. The goal of this study was to assess at the clinico-epidemiological characteristics of individuals with gastric cancer. Methods: This descriptive, cross- sectional study was conducted from November 2021 to October 2022, 120 patients with gastric cancer were included at Bangabandhu Sheikh Mujib Medical University (BSMMU), Department of Clinical Oncology. A pre-made questionnaire was used to collect data from patients during face-to-face interviews. Results: The mean age of the patients was 53.0 (±11.496) years, most of the patients (46.6%) were 51 – 60 years of age, 75.0 % of enrolled patients were male, 35.0 % of patients were service holder. The bulk of the cases had H. pylori infection (73.3%). The most common histological type among the patients was adenocarcinoma (95%). In terms of primary tumor location, the gastric antrum (50.0%) was the most prevalent subsite. Most of the patients were diagnosed as locally advanced stage. Conclusions: In conclusion, gastric cancer occurs mainly in middle aged males and associated with H. pylori infection. Adenocarcinoma is the most frequent histological form, with the gastric antrum as the main location of tumors and advanced stage.

14 March 2022 in Bangabandhu Sheikh Mujib Medical University Journal
Verified
Journal Article
Open access
PDF file
STSajib Kumar Talukdhar
Sajib Kumar Talukdhar
SASarwar Alam
Sarwar Alam
ABAbdul Bari
Abdul Bari
MSMohammad Jahan Shams
Mohammad Jahan Shams
SISohidul Islam
Sohidul Islam
NMNazir Uddin Mollah
Nazir Uddin Mollah
Concurrent chemoradiotherapy with or without induction chemotherapy is widely practiced in inoperable stage III and IVA/B head and neck cancer. The aim of this study was to investigate the survival and toxicity outcomes of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in inoperable stage III and IVA/B head and neck cancer patients. From June 2018 to July 2020, 86 patients participated in a quasi-experimental study. Patients were purposively assigned to one of the two arms (arm A or arm B). Arm A got induction chemotherapy and concurrent chemo- radiotherapy, while arm B got only concurrent chemoradiotherapy. According to our findings, the 2-year progression-free survival rate in arm A was 48.8% vs 37.2 % in arm B (p-value=0.042), and the 2-year overall survival rate in arm A was 65.1 % versus 60.5 % in arm B (p-value= 0.416). There were no statistically significant variations in treatment-related toxicities between the two groups (p-value > 0.05). In conclusion, inoperable stage III and IVA/B head and neck cancer patients who got induction chemotherapy plus concurrent chemotherapy had a better progression-free survival rate than those who received concur- rent chemoradiotherapy alone. BSMMU J 2021; 14(4): 144-147

14 July 2020 in Scholars Journal of Applied Medical Sciences
Verified
Journal Article
Closed access
NHNazmul Hasan
Nazmul Hasan
AMAbdullah – Al – Maruf
Abdullah – Al – Maruf
MBMohammed Mostanshir Billah
Mohammed Mostanshir Billah
IAImtiaz Ahmed
Imtiaz Ahmed
MSMohammad Jahan Shams
Mohammad Jahan Shams
ZBZillur Rahman Bhuiyan
Zillur Rahman Bhuiyan
Back ground: Biliary tract cancers refer to as group of cancers that arise from epithelial lining of the gall bladder and bile ducts peri-hilar and extra hepatic biliary tree and peri-ampullary tumors. Though biliary tract cancer is a rare entity. Objective: In this study our main goal is to evaluate the sociodemographic status of biliary tract carcinoma patients. Method: This cross-sectional study was conducted in Department of Oncology Bangabandhu Sheikh Mujib Medical University, Dhaka Medical College and National Institute of Cancer Research and Hospital, Dhaka from January 2018 to June 2019. 78patients with advanced biliary tract carcinoma (Stage IV), attending the out-Patient department were selected as sample where 39 patients received - Oral Capecitabine plus injectable Cisplatin (Arm-A) and 39 patients received injection Gemcitabine plus Cisplatin (Arm-B). Purposive sampling was done and data were analyzed by SSPS 21. Results: In this study, the majority of the patients were in the 50 to 59 years age groups in both the arms, range from 37 -70 years. Most of the patients were in the group 2 in both the arms. It was 51.29% and 56.41% in arm A & B respectively. 53.85% and 43.59% patients from Arm A and B had the primary tumor in the Gall Bladder respectively. 35.89% and 43.58% patients from Arm A and B respectively had the primary tumor in the Cholangiocarcinoma (CCA). On the other hand, 10.26% and 12.83% patients from Arm A and B had the primary tumor in the Periampullary Carcinoma respectively. Most of the patients (66.66% in Arm A and 66.66% in Arm B) had liver metastasis. Conclusion: In conclusion we can say that, this study demonstrated that, biliary tract cancers are a highly aggressive human malignancy that is difficult to diagnose. Most of the cases site of metastasis increase gradually which compare from similar studies in the literature.